Pariser DM et al., 2012-11-01: The two pivotal randomized, double-blind, vehicle-controlled trials behind the Sklice approval: one 10-minute application of 0.5% ivermectin lotion left 94.9% louse-free the next day without nit combing.
significantly more patients receiving ivermectin than patients receiving vehicle control were louse-free on day 2 (94.9% vs. 31.3%), day 8 (85.2% vs. 20.8%), and day 15 (73.8% vs. 17.6%)
Pariser DM et al., 2012-11-01: The two pivotal randomized, double-blind, vehicle-controlled trials behind the Sklice approval: one 10-minute application of 0.5% ivermectin lotion left 94.9% louse-free the next day without nit combing. Two multisite randomized double-blind vehicle-controlled trials; 765 patients completed; patients 6 months and older; single application to dry hair for 10 minutes then rinse; primary endpoint index patients louse-free at day 2 and remaining so through days 8 and 15; P<0.001 for each comparison. Comparator: vehicle lotion. Funder and conflicts not carried in the PubMed record; the product was developed by Sanofi/Arbor (Sklice) and the label is IVE-02. Full text paywalled; quote from the abstract. Study type: randomized trial.
